P3 Health Partners Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered officer introductions, voting on four key proposals, and confirmation of quorum. All proposals were approved, with final results to be published in a Form 8-K. No questions were submitted by stockholders.
-
Q1 delivered $26M adjusted EBITDA, exceeding expectations, with revenue up year-over-year despite lower membership. Structural improvements, disciplined execution, and favorable macro trends led to a raised 2026 outlook of $20–$60M adjusted EBITDA.
Fiscal Year 2025
-
Guidance for 2026 targets a $10 million Adjusted EBITDA midpoint, a $170 million improvement year-over-year, driven by contract, operational, and cost structure enhancements. Expansion into a new Medicare Advantage market adds 29,000 members and a multi-year glide path to risk.
-
Q3 results reflect a transitional year with stable medical cost trends, improved provider alignment, and a 6% increase in capitated revenue. Despite a $45.9M adjusted EBITDA loss, operational improvements and contract renegotiations position the business for profitability in 2026.
-
Operating in four states, the organization is focused on value-based care for seniors, leveraging a full-risk model and data-driven platform to drive profitability. Significant EBITDA improvements have been achieved, with further gains targeted for 2026, and membership growth expected to resume after network optimization.
-
Q2 results showed improved operational execution, with normalized EBITDA loss narrowing and medical cost trends flat year-over-year. Revised 2025 guidance reflects prior period headwinds and a single underperforming payer, but significant EBITDA improvement is expected in 2026 from contract, operational, and market changes.
-
Q1 2025 revenue declined 4% year-over-year to $373 million, with membership down 8% as part of a strategic exit from unprofitable plans. Operational improvements and contract renegotiations drove an 8% increase in per-member funding, and three of four markets reached break-even or better.
-
The conference highlighted a $130M+ turnaround plan, operational efficiencies, and technology adoption to drive growth and profitability in 2025 and beyond. Leadership emphasized value-based care, physician engagement, and positive industry tailwinds, with financial forecasts and enrollment updates expected soon.
Fiscal Year 2024
-
Revenue grew 18% year-over-year to $1.5B in 2024, with membership up 13% and improved operational efficiencies. 2025 guidance reaffirms revenue of $1.35B–$1.5B and targets profitability, supported by cost controls, benefit design changes, and expanded specialty contracts.
-
Q3 2024 saw 26% revenue growth and a 22% membership increase, but results were impacted by $35M in retroactive adjustments and elevated medical costs. Over $130M in improvement initiatives are underway, with profitability and cash flow expected to improve in 2025.
-
Post-pandemic demand and regulatory changes are driving market volatility and revenue pressure. The business is focused on deepening provider relationships, operational efficiencies, and technology upgrades, aiming for improved margins and cash flow positivity by late 2025.
-
Q2 revenue grew 15% year-over-year to $379M, with medical margin and adjusted EBITDA loss both improving sequentially. Membership and operational metrics exceeded guidance, and full-year outlook for revenue, margin, and EBITDA was reiterated, supported by strong cost controls and a recent capital raise.
-
Leadership highlighted strong experience in value-based care and outlined a strategy focused on deepening market penetration, operational efficiency, and technology partnerships. Financials show robust revenue and margin growth, with significant upside from improved coding and care management.
-
The presentation highlighted robust membership and revenue growth, operational efficiencies, and a strong value-based care model. Strategic initiatives include deeper market penetration, enhanced analytics partnerships, and disciplined execution to unlock significant EBITDA potential.